Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.53−0.08 (-4.97%)
Close on Nov 18, 2026Market cap $3.59MP/E –Yield –
Xenetic Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Xenetic Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$2.64M. For fiscal 2025 it was -$2.83M. The highest annual figure on record is -$2.83M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.83M | – |
| FY2024 | Dec 31, 2024 | -$4.20M | – |
| FY2023 | Dec 31, 2023 | -$4.52M | – |
| FY2022 | Dec 31, 2022 | -$6.72M | – |
| FY2021 | Dec 31, 2021 | -$5.75M | – |
| FY2020 | Dec 31, 2020 | -$13.94M | – |
| FY2019 | Dec 31, 2019 | -$12.89M | – |
| FY2018 | Dec 31, 2018 | -$7.28M | – |
| FY2017 | Dec 31, 2017 | -$3.57M | – |
| FY2016 | Dec 31, 2016 | -$47.43M | – |
| FY2015 | Dec 31, 2015 | -$9.82M | – |
| FY2014 | Dec 31, 2014 | -$12.92M | – |
| FY2013 | Dec 31, 2013 | -$8.61M | – |
| FY2012 | Dec 31, 2012 | -$6.34M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$971.69K | – |
| Q1 FY2026 | Mar 31, 2026 | -$502.12K | – |
| Q4 FY2025 | Dec 31, 2025 | -$623.03K | – |
| Q3 FY2025 | Sep 30, 2025 | -$544.73K | – |
| Q2 FY2025 | Jun 30, 2025 | -$724.41K | – |
| Q1 FY2025 | Mar 31, 2025 | -$942.41K | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$499.47K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.26M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$915.18K | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.38M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$982.46K | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.23M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.33M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.64M | -137.0% |
| Q3 FY2018 | Sep 30, 2018 | -$1.81M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.99M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.83M | – |
| Q4 FY2017 | Dec 31, 2017 | $4.43M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.24M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.90M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.86M | – |
| Q4 FY2016 | Dec 31, 2016 | -$64.43K | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.25M | – |
| Q2 FY2016 | Jun 30, 2016 | -$43.26M | – |
See a number that looks wrong?